Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

被引：2
|
作者：
Weisel, Katja [1 ]
Dimopoulos, Meletios A. [2 ]
San-Miguel, Jesus [3 ]
Paner, Agne [4 ]
Engelhardt, Monika [5 ]
Taylor, Fiona [6 ]
Lord-Bessen, Jennifer [7 ]
Yao, David [7 ]
Yip, Christine [8 ]
Greenwood, Mike [8 ]
Tang, Jackson [7 ]
Cavo, Michele [9 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Univ Navarra Clin, Pamplona, Spain
[4] Rush Univ Med Ctr, Chicago, IL USA
[5] Univ Med Ctr Freiburg, Freiburg, Germany
[6] Adelphi Values, Boston, MA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Adelphi Values, Bollington, England
[9] Bologna Univ, IRCCS Azienda Osped Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1662
引用
收藏
页数：6
相关论文
共 50 条
  • [41] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2014, 124 (21)
  • [42] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2020, 136
  • [43] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
    Weisel, Katja
    Hungria, Vania
    Quach, Hang
    Yoon, Sung-Soo
    Rodriguez-Otero, Paula
    Sinha, Arijit
    Boyapati, Anita
    Lyon, Charlotte
    Moore, Vygngley
    Inocencio, Tim
    Harnett, James
    Chi, Lei
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
  • [44] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Lonial, S.
    Palumbo, A.
    White, D.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Moreau, P.
    Mateos, M. -V.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Spencer, A.
    Oakervee, H.
    Taniwaki, M.
    Roellig, C.
    Wu, K. L.
    Singhal, A.
    San Miguel, J.
    Matsumoto, M.
    Katz, J.
    Bleickardt, E.
    Poulart, V.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 173 - 173
  • [45] Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth Carl
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil K.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey A.
    Martin, Thomas G., III
    Chen, Janice
    Brooks, Christopher
    McDonald, Peter
    Rupprecht, Nicole
    Wysowskyj, Halyna
    Chauhan, Dharminder
    Ray, Arghya
    Anderson, Kenneth C.
    Paba-Prada, Claudia E.
    BLOOD, 2019, 134
  • [47] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study
    Leleu, Xavier
    Lafore, Radhia
    Iaquinta, Daniel
    Tekle, Christina
    Rice, Megan
    Decaux, Olivier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S176 - S177
  • [48] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [49] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Kosh, Michele
    NamPhuong Tran
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2022, 140 : 7272 - 7274
  • [50] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
    Schjesvold, Fredrik H.
    Ludwig, Heinz
    Delimpasi, Sossana
    Robak, Pawel
    Coriu, Daniel
    Tomczak, Waldemar
    Pour, Ludek
    Spicka, Ivan
    Dimopoulos, Meletios-Athanasios
    Masszi, Tamas
    Chernova, Natalia G.
    Sandberg, Anna
    Thuresson, Marcus
    Norin, Stefan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2331 - 2336
12345